PDAC patients with serum HBsAg+ appear to show a worse prognosis
No differences are observed with regards to T stage, vascular invasion,
lymph node metastasis, and peri-neural invasion between
PDAC patients with serum HBsAg− or HBsAg+. Overall survival (OS)
is shorter in patients with serum HBsAg+ (median survival time,
8 vs. 13 months, P = 0.310, Fig. 1A). Since overall survival can be affected
by postoperative treatments, such as chemotherapy,
stratification analysis, according to the frequency of chemotherapy
(